When and how to use data from randomised trials to develop or validate prognostic models

Autor: L. M. Peelen, Karel G. M. Moons, Romin Pajouheshnia, Johannes B. Reitsma, Rolf H.H. Groenwold
Přispěvatelé: Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology
Jazyk: angličtina
Rok vydání: 2019
Předmět:
Zdroj: The BMJ, 365. BMJ Publishing Group
British Medical Journal, 365. BMJ Publishing Group Ltd
ISSN: 0959-8146
1756-1833
Popis: Prediction models have become an integral part of clinical practice, providing information for patients and clinicians and providing support for their shared decision making. The development and validation of prognostic prediction models requires substantial volumes of high quality information on relevant predictors and patient health outcomes. Primary data collection dedicated to prognostic model (development or validation) research could come with substantial time and costs and can be seen as a waste of resources if suitable data are already available. Randomised clinical trials are a source of high quality clinical data with a largely untapped potential for use in further research. This article addresses when and how data from a randomised clinical trial can be used additionally for prognostic model research, and provides guidance for researchers with access to trial data to evaluate the suitability of their data for the development and validation of prognostic prediction models.
Databáze: OpenAIRE